Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Fosifloxuridine Nafalbenamide
DRUG
2 trials
Sponsors
NuCana plc
Conditions
Advanced Cancer
Advanced Solid Tumor
Classical Hodgkin Lymphoma
Colorectal Adenocarcinoma
Colorectal Cancer
Colorectal Cancer Metastatic
Colorectal Neoplasms
Endometrial Carcinoma
+14 more
Phase 1
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Terminated
NCT05714553
NuCana plc
Advanced Cancer, Advanced Solid Tumor, Classical Hodgkin Lymphoma +14
Start: 2023-03-08
End: 2025-05-30
Updated: 2026-07-23
Phase 2
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
Terminated
NCT05678257
NuCana plc
Colorectal Adenocarcinoma, Colorectal Cancer, Colorectal Cancer Metastatic +2
Start: 2023-04-18
End: 2024-08-29
Updated: 2025-09-12
Related Papers
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
2024-04-02
5 citations
Abstract C029: Phase Ib/II open label, multi-arm, parallel cohort dose finding and expansion study of NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors or docetaxel in patients with lung cancer (NuTide:303)
Molecular Cancer Therapeutics
2023-12-01
1 citations
Abstract B049: Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs FOLFIRI + bevacizumab for the second-line treatment of patients with advanced/metastatic colorectal cancer (NuTide:323)
Molecular Cancer Therapeutics
2023-12-01